...AB Bristol-Myers Squibb Co. (NYSE:BMY) Novo Seeds Pulmonary Single target 2014 2017 Phase Ib/IIa complete F-star Alpha Ltd....

...Ltd. (Cambridge, U.K.) said Bristol-Myers Squibb Co. (NYSE:BMY) will not exercise an option to acquire F-star Alpha Ltd....
...across its oncology portfolio.” In 2014, F-star Biotechnology granted BMS an exclusive option to acquire F-Star Alpha...
...begin a Phase IIb trial. BMS was funding the compound's development. F-star Biotechnology spun out F-star Alpha...

...Ltd. (Cambridge, U.K.) said Bristol-Myers Squibb Co. (NYSE:BMY) will not exercise an option to acquire F-star Alpha Ltd....
...breast and gastric cancer. In 2014, F-star Biotechnology granted BMS an exclusive option to acquire F-Star Alpha...
...of opportunities across its oncology portfolio” (see BioCentury, Nov. 3, 2014) . Jaime De Leon FS102 Bristol-Myers Squibb Co. F-star Alpha Ltd. F-star...

...rights to the Fc antibody fragment targeting HER2 from F-star Alpha (see BioCentury, Nov. 3, 2014). F-star Alpha Ltd....

...Bristol-Myers Squibb Co. (NYSE:BMY) paid $50 million for an exclusive option to acquire the biotech's F-star Alpha Ltd....
...unit, which had a preclinical antibody fragment that is now in Phase I for cancer. F-star Alpha...

...Beta's license spans 22 undisclosed oncology and immuno-oncology targets that F-star had previously licensed to F-star Alpha...
...antibodies. F-star Beta is the second asset-centric company F-star Biotechnology has created. It spun out F-star Alpha Ltd....
...Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) agreed to pay up to $475 million to F-star Alpha...

...undisclosed. F-star Beta is the second asset-centric company F-star Biotechnology has created. It spun out F-star Alpha Ltd....
...week with Bristol-Myers Squibb Co. (NYSE:BMY). BMS agreed to pay up to $475 million to F-star Alpha...
...period (see BioCentury, Nov. 3) . Haurum said F-star Beta's shareholders are the same as F-star Alpha's...

...Bristol-Myers Squibb received an exclusive option to acquire F-star Alpha and gain worldwide rights to FS102...
...F-star GmbH (Vienna, Austria) spun out F-star Alpha last year to house FS102. BMS will pay F-star Alpha...
...IIb testing and three-and-a-half years after starting Phase I testing. If BMS exercises the option, F-star Alpha's...

...convenience and seller financial flexibility. F-star Biotechnology Ltd., a subsidiary of F-star GmbH , launched F-star Alpha...

...Bristol-Myers Squibb Co. (NYSE:BMY) obtained an exclusive option to acquire F-star Alpha Ltd. (Cambridge, U.K.). The Cambridge-based F-star...
...Cambridge, U.K.). The Cambridge-based F-star Biotechnology Ltd subsidiary of F-star GmbH (Vienna, Austria) spun out F-star Alpha...
...growth factor receptor 2 ( EGFR2 ; HER2 ; ErbB2 ; neu). BMS will pay F-star Alpha...